Compare Abeona Therapeutics Inc (ABEO) vs Colgate-Palmolive Company (CL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Colgate-Palmolive Company — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Colgate-Palmolive Company trades at $92.43 (market cap $74.26B). The key difference: Colgate-Palmolive Company is far larger — about 175× Abeona Therapeutics Inc's market cap, and Colgate-Palmolive Company pays a 2.28% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CL | |
|---|---|---|
Market Cap | $424.33M | $74.26B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $99.14 |
52-Week Low | $4.17 | $74.98 |
Enterprise Value | $279.23M | $80.74B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Colgate-Palmolive (CL) trades at $93.27, up 0.29% on the day, with a bullish technical signal and consistent earnings beats. The company reported Q2 2026 EPS of $0.99, exceeding estimates, driven by strong margins and organic growth in emerging markets, though North American performance remains weak. Operating cash flow remains robust at $4.2 billion in 2025, supporting shareholder returns.
Outlook is mixed: valuation appears stretched with a P/E of 36.72, but analyst consensus targets $99.10. Risks include competitive pressures in North America and high debt levels. The stock offers a stable dividend, but growth concerns and insider selling warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →
